Drugs in Dev. Endocrinology
Phase I
Italy 
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement
Details : Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.
Product Name : NP-500
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : NP-500
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Atlas Sciences
Deal Size : $1.5 million
Deal Type : Licensing Agreement
Reset All
